1. Home
  2. BOLT vs AIRE Comparison

BOLT vs AIRE Comparison

Compare BOLT & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

HOLD

Current Price

$3.97

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

Logo reAlpha Tech Corp.

AIRE

reAlpha Tech Corp.

HOLD

Current Price

$1.42

Market Cap

11.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOLT
AIRE
Founded
2015
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
11.5M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
BOLT
AIRE
Price
$3.97
$1.42
Analyst Decision
Strong Buy
Buy
Analyst Count
3
3
Target Price
$34.00
$1.30
AVG Volume (30 Days)
16.1K
64.2K
Earning Date
05-13-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.34
EPS
N/A
N/A
Revenue
$7,695,000.00
$4,518,498.00
Revenue This Year
N/A
$129.06
Revenue Next Year
$133.33
$83.72
P/E Ratio
N/A
N/A
Revenue Growth
0.07
376.42
52 Week Low
$3.75
$0.16
52 Week High
$7.20
$3.98

Technical Indicators

Market Signals
Indicator
BOLT
AIRE
Relative Strength Index (RSI) 47.76 40.09
Support Level $3.90 $0.29
Resistance Level $4.46 $2.17
Average True Range (ATR) 0.24 0.16
MACD 0.01 -0.03
Stochastic Oscillator 39.10 18.75

Price Performance

Historical Comparison
BOLT
AIRE

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.

Share on Social Networks: